basher? Seris of international launches is a great thing
Analysts Confident in Fitbit Inc’s (FIT) Ability to Dominate Fitness Wearables Market
By Cody Miecnikowski
The company has continued to show momentum along with brand leadership, an expanding product line, and growing sales. Fitbit is on track to grow and penetrate a large share of the global fitness market. In regards to paid services, “Fitbit’s longer-term aspiration is to drive additional revenue streams from software and services fees, capitalizing on its device and app. customer base. To this end, it recently acquired FitStar to enhance its online software capabilities. This is also a major focus of its current R&D efforts. The global fitness market exceeds $200 billion annually, signifying a huge opportunity for the company. The healthier lifestyle change we’re seeing in the US is being mirrored overseas and international contributes about 25% of sales, offering substantive growth opportunities.”
Alirocumab AdComm Net Positive for Esperion Therapeutics (ESPR) ETC-1002, Needham & Company Says
Needham & Company analyst Chad Messer reiterated a Buy rating and $130 price target on Esperion Therapeutics (NASDAQ: ESPR) following a read-through from Alirocumab AdComm, which they view as a net positive for ETC-1002.
Oncothyreon Inc. (NASDAQ: ONTY) has two abstracts related to ONT-380 for the treatment of breast cancer published for ASCO.
your against 10 million bulls and noone going to short this at $2, Going much higher
Juno Therapeutics ( JUNO ) beginning a gap up.